Nuvectis Pharma Announces the Initiation of the Phase 1b Study of NXP900 in Combination with Osimertinib in Patients with NSCLCGlobeNewsWire • 12/17/25
Nuvectis Pharma to Host a Virtual Key Opinion Leader Meeting to Discuss the NXP900 Phase 1b Program in Advanced Solid Tumors, Including the Combination with Osimertinib in NSCLCGlobeNewsWire • 11/25/25
CORRECTION: Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business HighlightsGlobeNewsWire • 11/04/25
Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsGlobeNewsWire • 10/16/25
Nuvectis Pharma to Participate at the H.C. Wainwright 27th Annual Global Investment ConferenceGlobeNewsWire • 09/04/25
Nuvectis Pharma, Inc. Reports Second Quarter 2025 Financial Results and Business HighlightsGlobeNewsWire • 08/05/25
Nuvectis Pharma Provides Final Clinical Data Update from the NXP800 Phase 1b Study in Ovarian Cancer and Reports Completion of the NXP900 Phase 1a Dose Escalation StudyGlobeNewsWire • 07/31/25
Nuvectis Pharma to Present at the H.C. Wainwright BioConnect Investor ConferenceGlobeNewsWire • 05/16/25
Does Nuvectis Pharma (NVCT) Have the Potential to Rally 108.79% as Wall Street Analysts Expect?Zacks Investment Research • 05/09/25
Nuvectis Pharma, Inc. Reports First Quarter 2025 Financial Results and Business HighlightsGlobeNewsWire • 05/06/25
Nuvectis Pharma Provides Poster Presentation Highlights for NXP900 from the 2025 AACR MeetingGlobeNewsWire • 04/29/25
Market News Alert: Nuvectis Pharma's NXP900 Demonstrates Superior Efficacy in NSCLC When Combined with Tagrisso in Cleveland Clinic Study, Following New Buy RecommendationBusiness Wire • 03/05/25
Market News Alert: Nuvectis Pharma Receives $18 Price Target and Buy Rating from Lucid Capital MarketsBusiness Wire • 02/27/25
Nuvectis Pharma Announces Closing of $15.5 Million Public Offering of Common Stock and Full Exercise of Underwriter's Over-Allotment OptionGlobeNewsWire • 02/07/25
Nuvectis Pharma Announces Pricing of $13.5 Million Public Offering of Common StockGlobeNewsWire • 02/05/25
Nuvectis Pharma (NVCT) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?Zacks Investment Research • 11/25/24
Nuvectis Pharma CEO Says Increased Dose Intensity Needed To Drive More Efficacy From Ovarian Cancer Lead DrugBenzinga • 11/14/24
Nuvectis Pharma (NVCT) Is a Great Choice for 'Trend' Investors, Here's WhyZacks Investment Research • 11/13/24
Wall Street Analysts Predict a 169.94% Upside in Nuvectis Pharma (NVCT): Here's What You Should KnowZacks Investment Research • 11/07/24
Nuvectis Pharma, Inc. Reports Third Quarter 2024 Financial Results and Business HighlightsGlobeNewsWire • 11/05/24
PESG Releases Market Update: Nuvectis Pharma Shows Promising Synergy for NXP900 in Recent Presentations; Growing Anticipation for Upcoming NXP800 Data UpdateBusiness Wire • 10/28/24